Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Receivables (2021 - 2025)

Historic Receivables for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.3 billion.

  • Rxo's Receivables rose 64.31% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 64.31%. This contributed to the annual value of $1.3 billion for FY2025, which is 64.31% up from last year.
  • Per Rxo's latest filing, its Receivables stood at $1.3 billion for Q4 2025, which was up 64.31% from $1.1 billion recorded in Q3 2025.
  • Rxo's 5-year Receivables high stood at $1.3 billion for Q4 2025, and its period low was $716.0 million during Q1 2024.
  • For the 5-year period, Rxo's Receivables averaged around $965.1 million, with its median value being $1.0 billion (2022).
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 2261.55% in 2023, then soared by 6498.67% in 2024.
  • Over the past 5 years, Rxo's Receivables (Quarter) stood at $1.0 billion in 2021, then decreased by 11.76% to $900.0 million in 2022, then decreased by 16.22% to $754.0 million in 2023, then skyrocketed by 64.99% to $1.2 billion in 2024, then increased by 0.64% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.1 billion for Q3 2025, and $1.1 billion during Q2 2025.